HC-5404, our first adaptive stress product candidate, is a differentiated highly selective, orally bioavailable inhibitor of a key stress response protein kinase, PERK. We are developing HC-5404 for stress driven tumors, including von Hippel-Lindau, or VHL, mutated RCC, gastric cancer and other solid tumors.

HC-7366, our second adaptive stress product candidate, is a differentiated selective, orally bioavailable modulator of another key stress response protein kinase, GCN2.  We are developing HC-7366 for the treatment of advanced solid tumors and are exploring the potential of HC-7366 in hematological malignancies.

Odetiglucan (Imprime PGG) is our systemically administered innate and adaptive immune modulator therapeutic candidate.   We are conducting a Phase 2 clinical trial of Odetiglucan in combination with pembrolizumab in adults with metastatic, hormone-refractory breast cancer patients and plan to submit INDs for Phase 1b clinical trials in combination with a CD40 agonistic antibody in pancreatic cancer and as monotherapy in liver metastasis.